Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ALPK1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ALPK1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ALPK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
GO:00431228 | Cervix | CC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2311 | 249/18723 | 4.50e-05 | 6.87e-04 | 53 |
GO:00022212 | Cervix | CC | pattern recognition receptor signaling pathway | 39/2311 | 172/18723 | 1.08e-04 | 1.38e-03 | 39 |
GO:00072497 | Cervix | CC | I-kappaB kinase/NF-kappaB signaling | 56/2311 | 281/18723 | 1.81e-04 | 2.12e-03 | 56 |
GO:00027534 | Cervix | CC | cytoplasmic pattern recognition receptor signaling pathway | 18/2311 | 60/18723 | 2.26e-04 | 2.55e-03 | 18 |
GO:00431237 | Cervix | CC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 37/2311 | 186/18723 | 2.15e-03 | 1.55e-02 | 37 |
GO:00305227 | Lung | IAC | intracellular receptor signaling pathway | 59/2061 | 265/18723 | 8.88e-08 | 8.50e-06 | 59 |
GO:00072495 | Lung | IAC | I-kappaB kinase/NF-kappaB signaling | 56/2061 | 281/18723 | 7.39e-06 | 2.62e-04 | 56 |
GO:00431226 | Lung | IAC | regulation of I-kappaB kinase/NF-kappaB signaling | 51/2061 | 249/18723 | 8.41e-06 | 2.87e-04 | 51 |
GO:00431235 | Lung | IAC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 38/2061 | 186/18723 | 1.19e-04 | 2.25e-03 | 38 |
GO:0060271 | Lung | IAC | cilium assembly | 55/2061 | 337/18723 | 1.84e-03 | 1.88e-02 | 55 |
GO:0044782 | Lung | IAC | cilium organization | 58/2061 | 368/18723 | 3.15e-03 | 2.75e-02 | 58 |
GO:00027643 | Lung | IAC | immune response-regulating signaling pathway | 70/2061 | 468/18723 | 4.79e-03 | 3.72e-02 | 70 |
GO:003052213 | Lung | AIS | intracellular receptor signaling pathway | 53/1849 | 265/18723 | 4.57e-07 | 3.55e-05 | 53 |
GO:004312213 | Lung | AIS | regulation of I-kappaB kinase/NF-kappaB signaling | 41/1849 | 249/18723 | 7.57e-04 | 1.08e-02 | 41 |
GO:000724913 | Lung | AIS | I-kappaB kinase/NF-kappaB signaling | 45/1849 | 281/18723 | 7.90e-04 | 1.11e-02 | 45 |
GO:000724922 | Lung | AAH | I-kappaB kinase/NF-kappaB signaling | 21/613 | 281/18723 | 4.01e-04 | 1.78e-02 | 21 |
GO:004312222 | Lung | AAH | regulation of I-kappaB kinase/NF-kappaB signaling | 19/613 | 249/18723 | 5.79e-04 | 2.23e-02 | 19 |
GO:003052228 | Thyroid | PTC | intracellular receptor signaling pathway | 126/5968 | 265/18723 | 6.31e-08 | 1.31e-06 | 126 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALPK1 | SNV | Missense_Mutation | | c.484N>G | p.Leu162Val | p.L162V | Q96QP1 | protein_coding | deleterious(0.02) | benign(0.275) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALPK1 | SNV | Missense_Mutation | | c.1310N>C | p.Phe437Ser | p.F437S | Q96QP1 | protein_coding | deleterious(0) | benign(0.074) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALPK1 | SNV | Missense_Mutation | | c.2049N>A | p.Phe683Leu | p.F683L | Q96QP1 | protein_coding | tolerated(0.68) | benign(0) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALPK1 | SNV | Missense_Mutation | rs551402838 | c.3262N>A | p.Ala1088Thr | p.A1088T | Q96QP1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
ALPK1 | SNV | Missense_Mutation | novel | c.502N>A | p.Leu168Met | p.L168M | Q96QP1 | protein_coding | deleterious(0) | probably_damaging(0.937) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
ALPK1 | SNV | Missense_Mutation | novel | c.2401N>T | p.Asp801Tyr | p.D801Y | Q96QP1 | protein_coding | deleterious(0.01) | benign(0.122) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
ALPK1 | SNV | Missense_Mutation | novel | c.1856C>A | p.Thr619Asn | p.T619N | Q96QP1 | protein_coding | tolerated(0.17) | benign(0.296) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ALPK1 | SNV | Missense_Mutation | | c.3284N>G | p.Phe1095Cys | p.F1095C | Q96QP1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
ALPK1 | SNV | Missense_Mutation | | c.505A>G | p.Ser169Gly | p.S169G | Q96QP1 | protein_coding | deleterious(0.01) | benign(0.017) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALPK1 | SNV | Missense_Mutation | | c.980A>G | p.Glu327Gly | p.E327G | Q96QP1 | protein_coding | deleterious(0) | possibly_damaging(0.469) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |